Checkpoint inhibitors and the gut

Tuan Tran; Nguyen Giang Tien Tran; Vincent Ho

Checkpoint inhibitors and the gut

Tuan Tran, Nguyen Giang Tien Tran, Vincent Ho

Western Sydney University

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Checkpoint inhibitors have revolutionized treatments in modern oncology, including many conditions previously relegated to palliative therapies only. However, emerging recognition of checkpoint inhibitor-related adverse events has complicated the status of checkpoint inhibitor-related therapies. This review article discusses gastrointestinal adverse events as a result of checkpoint inhibitor therapy, as well as limitations of current guidelines, thus providing recommendations for guideline revision and future study direction.

Original language	English
Article number	824
Number of pages	13
Journal	Journal of Clinical Medicine
Volume	11
Issue number	3
Publication status	Published - 2022

Open Access - Access Right Statement

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{f3346600ad604554bcac2af01e50ed9d,

title = "Checkpoint inhibitors and the gut",

abstract = "Checkpoint inhibitors have revolutionized treatments in modern oncology, including many conditions previously relegated to palliative therapies only. However, emerging recognition of checkpoint inhibitor-related adverse events has complicated the status of checkpoint inhibitor-related therapies. This review article discusses gastrointestinal adverse events as a result of checkpoint inhibitor therapy, as well as limitations of current guidelines, thus providing recommendations for guideline revision and future study direction.",

author = "Tuan Tran and Tran, {Nguyen Giang Tien} and Vincent Ho",

year = "2022",

language = "English",

volume = "11",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

publisher = "MDPI AG",

number = "3",

}

TY - JOUR

T1 - Checkpoint inhibitors and the gut

AU - Tran, Tuan

AU - Tran, Nguyen Giang Tien

AU - Ho, Vincent

PY - 2022

Y1 - 2022

N2 - Checkpoint inhibitors have revolutionized treatments in modern oncology, including many conditions previously relegated to palliative therapies only. However, emerging recognition of checkpoint inhibitor-related adverse events has complicated the status of checkpoint inhibitor-related therapies. This review article discusses gastrointestinal adverse events as a result of checkpoint inhibitor therapy, as well as limitations of current guidelines, thus providing recommendations for guideline revision and future study direction.

AB - Checkpoint inhibitors have revolutionized treatments in modern oncology, including many conditions previously relegated to palliative therapies only. However, emerging recognition of checkpoint inhibitor-related adverse events has complicated the status of checkpoint inhibitor-related therapies. This review article discusses gastrointestinal adverse events as a result of checkpoint inhibitor therapy, as well as limitations of current guidelines, thus providing recommendations for guideline revision and future study direction.

UR - https://hdl.handle.net/1959.7/uws:62416

M3 - Article

SN - 2077-0383

VL - 11

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 3

M1 - 824

ER -

Checkpoint inhibitors and the gut

Abstract

Open Access - Access Right Statement

UN SDGs

Other files and links

Fingerprint

Cite this